Pre-workout Supplementation and Basketball

NCT06059911 | Unknown

• 1 other identifier: Douligeris Study
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Pre-workout supplements (PWS) consumption in recreationally or physically trained males lead to many performance-enhancing benefits, including improvements in mean power output during single and repeated sprints, agility, reaction times, lower body muscular endurance and reduced fatigue. PWS ingestion also improves anaerobic performance and prolongs time to exhaustion during high-intensity intermittent exercise. However, PWSs' effectiveness is not constant, as they do not alter anaerobic power, jumping performance or blood lactate concentrations after a training session, at least in recreationally trained males and strength-power athletes. Moreover, the effects of long-term PWS supplementation, where some nutritional agents were combined (e.g., β-alanine, creatine, citrulline malate, etc.) to assess endurance-trained runners or elite cyclists' performance, are mixed and less clear. Even though the popularity of PWS use has increased among trained/professional athletes, most of the data in this area are derived from recreationally and not from well-trained athletes of a competitive level (especially in team sports). Therefore, the present study aimed to examine the acute and chronic effects of a PWS, containing 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g βalanine, 6 g citrulline malate and 5 g BCAA per dose, on shooting, jumping, sprinting, agility, aerobic and anaerobic performance in well-trained basketball players.

Conditions

Sport Performance

Outcome Measures

Primary Outcomes (15)

• Countermovement jump height

  Jumping performance will be evaluated using a contact platform

  baseline and up to 4 weeks

• 20 meters sprint running time

  Sprint performance will be evaluated using photocell gates

  baseline and up to 4 weeks

• Rate of agility T-test performance

  Agility T-test will be evaluated using photocell gates

  baseline and up to 4 weeks

• Rate of running-based anaerobic sprint test performance

  Running-based anaerobic sprint test performance will be evaluated using photocell gates

  baseline and up to 4 weeks

• Rate of Yo-Yo intermittent recovery test level 1 test performance

  Yo-Yo intermittent recovery test level 1 test performance will be evaluated using a field-based test

  baseline and up to 4 weeks

• Rate of basketball-specific shooting performance

  Basketball-specific shooting performance will be evaluated with a test consisting of 30 free shoots, 30 middle-distance shoots and 30 long-distance shoots

  baseline and up to 4 weeks

• Blood lactate concentartion

  Blood lactate concentration will be measured using a portable blood lactate analyzer

  baseline and up to 4 weeks

• Creatine kinase concentration

  Creatine kinase activity will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Lactate dehydrogenase concentration

  Lactate dehydrogenase will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Alkaline phosphatase concentration

  Alkaline phosphatase will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Gamma-glutamyltransferase concentration

  Gamma-glutamyltransferase will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Urea concentration

  Urea will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Creatinine concentration

  Creatinine will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Serum glutamic-oxaloacetic transaminase activity

  Serum glutamic-oxaloacetic transaminase will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

• Serum glutamate-pyruvate transaminase activity

  Serum glutamate-pyruvate transaminase will be measured on a clinical chemistry analyzer

  baseline and up to 4 weeks

Secondary Outcomes (5)

• Body mass

  baseline and up to 4 weeks

• Body height

  baseline and up to 4 weeks

• Body fat mass

  baseline and up to 4 weeks

• Systolic and diastolic blood pressure

  baseline and up to 4 weeks

• Heart rate

  baseline and up to 4 weeks

Study Arms (2)

Multi-ingredient dietary supplement

EXPERIMENTAL

20 g of a multi-ingredient dietary supplement. Composition: 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g BCAA

Dietary Supplement: Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA)

Placebo dietary supplement (97% maltodextrin)

PLACEBO COMPARATOR

20 g of isoenergetic placebo dietary supplement. Composition: 97% flavored maltodextrin, similar in color, flavor, taste and energy to the experimental multi-ingredient supplement

Dietary Supplement: Placebo dietary supplement (97% maltodextrin)

Interventions

Multi-ingredient dietary supplement (caffeine, creatine monohydrate, β-alanine, citrulline malate, BCAA) DIETARY_SUPPLEMENT

Administration of a multi-ingredient dietary supplement consisting of 200 mg caffeine, 3.3 g creatine monohydrate, 3.2 g β-alanine, 6 g citrulline malate and 5 g branched chain amino acids

Multi-ingredient dietary supplement

Placebo dietary supplement (97% maltodextrin) DIETARY_SUPPLEMENT

Administration of an isoenergetic placebo comparator dietary supplement consisting of 97% maltodextrin

Placebo dietary supplement (97% maltodextrin)

Eligibility Criteria

• Age: 18 Years - 41 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male participants, 18-41 years old
• Absence of drugs, abuse or medications, which are known to affect the Shooting, sprinting, jumping, agility, anaerobic and endurance performance
• Consent to follow a regular dietary plan for basketball players

You may not qualify if:

• Restraining orthopedic/neuromuscular problems
• Caffeine hypersensitivity
• Consumption of more than three servings of coffee per day
• Use of any supplement or steroids prior to the study
• Use of creatine, β-alanine, citrulline malate or BCAA-protein supplementation at least six months before the initiation of the study

Sponsors & Collaborators

• Athanasios Z. Jamurtas: lead

Study Sites (1)

Sports Nutrition Laboratory, International Hellenic University

Thessaloniki, Greece

Location

MeSH Terms

Interventions

Caffeine; Creatine; citrulline malate; maltodextrin

Intervention Hierarchy (Ancestors)

Xanthines; Alkaloids; Heterocyclic Compounds; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Guanidines; Amidines; Organic Chemicals; Amino Acids; Amino Acids, Peptides, and Proteins

Study Officials

• Sousana K Papadopoulou

  International Hellenic University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 15, 2023
• First Posted: September 29, 2023
• Study Start: June 15, 2022
• Primary Completion: December 15, 2023
• Study Completion: June 15, 2024
• Last Updated: October 3, 2023

Record last verified: 2023-09

Locations

GR (1)